Resources for your practice

Let us help your patients access Xiidra®. You focus on treating their dry eye disease.

sticky line
Resources for your practice
sticky line

Resources for your practice

Let us help your patients access Xiidra®. You focus on treating their dry eye disease.

Need Xiidra samples?

Xiidra® (lifitegrast ophthalmic solution) 5% package

Tip: When completing the request-a-rep form, select “Other” in the subject field, then type Request a rep/samples in the “Other” field.

REMEMBER

Your office can also initiate a PA—being proactive in the PA process may help improve your patient’s access to Xiidra.

Digital education for eye care technicians

tech talks laptop

Novartis’ commitment to developing educational content that is relevant to eye care technicians includes Tech Talks. This series of short videos is designed to support the technician’s critical role in helping dry eye patients. Find the whole series on dryeyetech.com.

tech talks laptop
labtech

Thought leader perspectives

Approaching DED in Presurgical Patients

Discover his preferred treatment and management plan for DED in patients who are presenting for surgery, from Dr. Richard Lindstrom, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants, Chief Medical Officer and Board Member at TLC Laser Eye Centers, Senior Lecturer and Trustee Emeritus of the Foundation at the University of Minnesota and Visiting Professor at the UC Irvine Gavin Herbert Eye Institute. Dr. Lindstrom is a paid consult for Novartis.

Dr. Lindstrom

Approaching DED in Presurgical Patients

Richard L. Lindstrom, MD

Founder and Attending Surgeon

Emeritus at Minnesota Eye Consultants
Chief Medical Office and Board Member at TLC Laser Eye Centers

Dr. Lindstrom is a paid consultant for Novartis Pharmaceuticals Corporation, the maker of Xiidra.

Discover his preferred treatment and management plan for DED in patients who are presenting for surgery, from Dr. Richard Lindstrom, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants, Chief Medical Officer and Board Member at TLC Laser Eye Centers, Senior Lecturer and Trustee Emeritus of the Foundation at the University of Minnesota and Visiting Professor at the UC Irvine Gavin Herbert Eye Institute. Dr. Lindstrom is a paid consult for Novartis.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.